Skip to main content
. 2022 Aug 26;13:948353. doi: 10.3389/fgene.2022.948353

FIGURE 9.

FIGURE 9

RRM1 expression in low- and high-risk groups (A). Etoposide, cisplatin and doxorubicin senstivity in low- and high-risk groups (B–D).